pharmaceuticals

pharmaceuticals Articles

If there is one former Dow Jones industrial average leader that is in need of serious help, look no further than General Electric.
The 55th annual meeting of the American Society of Clinical Oncology (ASCO) is just around the corner. Biotech and pharmaceutical companies will descend on Chicago for a five-day all-out conference...
The April 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Mylan released mixed first-quarter financial results before the markets opened on Tuesday, and share plunged afterward.
With healthy living trends gaining ever more traction within the United States, they provide ample investment opportunity. ETFs help mitigate the risk of investing in individual fitness companies or...
Osmotica Pharma shares jumped on Tuesday after the firm announced results from its late-stage trial for the treatment of ptosis (droopy eyelid).
Mylan is scheduled to release its first-quarter financial results before the markets open on Tuesday, and earnings are expected to be lower than a year ago.
The April 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
24/7 Wall St. has looked over some of the biotech sector's laggards, and we have also looked over the top exchange-traded funds for a breakdown of what they own to show how much they are lagging...
Jefferies did a deep dive into the health care sector, looking for underperforming stocks that could hold some solid value going forward.
Johnson & Johnson released better-than-expected first-quarter financial results before the markets opened on Tuesday.
Johnson & Johnson is scheduled to release its first-quarter financial results before the markets open on Tuesday, and expectations are muted.
The March 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with two major movers in the group.
Alnylam Pharma and Regeneron Pharma shares dipped on Monday despite announcing a collaboration to discover, develop and commercialize new RNA interference therapeutics for a broad range of diseases.
Sangamo Therapeutics shares jumped on Tuesday after the company announced interim data from its midstage hemophilia trial in collaboration with Pfizer.